India's Lupin Pharmaceuticals Inc. (500257,LUPIN) on Thursday said it won the final approval from U.S. Food and Drugs Administration, or FDA, to market its anti-depressant drug, escitalopram tablets, a generic version of Forest Laboratories' lexapro tablets in the U.S.
In addition, Lupin said it was the only Asian company to achieve the distinction of being the fifth largest generics player in the U.S.
Lupin's Escitalopram Tablets will be used to treat adults and children between 12-17 years and who suffer from major depressive and anxiety disorders in adults.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.